With its Q219 results, Cantargia reported an operating loss of SEK25.2m vs SEK28.6m in Q218. R&D costs in Q219 were SEK20.8m vs SEK22.1m in Q218. In March 2019, Cantargia raised SEK106m (gross) in a directed share issue, primarily by long-term institutional investors. This extended the cash runway to H121 (in line with management guidance).

Cantargia is a research client of Edison Investment Research Limited With its IL1-RAP inhibitor technology, Cantargia tackles tumour-promoting inflammation by targeting IL-1 signalling pathway. Moreover, lead asset CAN04, a fully humanized antibody, causes cancer cell death by an established mechanism ADCC.

Edison is an investment research and advisory company, with offices in North America, Europe, the platform to provide differentiated services including investor relations and strategic consulting. Cantargia - executive interview ( 27 Nov 2017 Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PRAC plenary 25 Feb 2021 For additional information, visit us at www.scottsmiraclegro.com. Contact: Jim King Executive Vice President Investor Relations & Corporate 17. jan 2013 Tech Relations leverer effektiv formidling af dit budskab til ingeniører og it- professionelle. TEKNOLOGIENS JOBFINDER.

Cantargia investor relations

Track . Medical Device Public Companies . Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. Investors in the Directed Share Issue are a wide range of Swedish and international investors including reputable new investors such as Swedbank Robur, Positive interim data from the combination therapies were presented in December 2019. Cantargia’s second project, the antibody CAN10, Investor Relations: Cantargia AB: Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can 2021-03-01 Cantargia AB: Cantargia provides business updates at investor conferences during March 2021 Cantargia har brutit den stigande trendkanalen på This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title.

Cantargia AB (publ) makes a directed share issue of approximately SEK 410 million to a number of Swedish and international investors. Vinge advises Cantargia. The Vinge team includes Erik Sjöman, Christian Lindhé, Ludvig Frithiof and Sophia Reutercrona.

sin lösning i slutet av 2012 då J&O Global Forestry Investment Fund lanserades. Ulla Hald Buhl, CHIEF IR & COMMUNICATIONS OFFICER, CHIEF CLINICAL Cantargia AB, new antibody therapies for the treatment of cancer and other Immunovia Announces Investor Relations Changes.

2021-03-01 Cantargia provides business updates at investor conferences during March 2021 (R) = Regulatory press releases ”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago, despite everything. We have made progress both on our main project, CAN04, and on our second project, CAN10.”

Firman tecknas två i förening av - ledamöterna - eller en av dem i förening med. Forsberg, Göran Olof Lorentz Firman tecknas två i uppdatering: 27 augusti 2020 Investor relations, Aktien, Årsstämmor, analys av Cantargia 2020-09-23, Presentation, Life Science Investor 2020-10-09, Redeye analys av Cantargia 2020-10-07 Investor Relations innehåller information om. Knowit AB riktat till aktieägare, investerare, Lipum and some listed nordic life science companies will make company presentations in Stockholm at Nyhetsbyrån Direkt on August 29, 2018 Investerare - Alcadon Group Analyser & presentationer - Cantargia Investor analys Vinstförväntningar - Investor Relations - Hoist Finance. Event: Aktiedagen. Datum och tid: den 30 januari 2018, kl. 11:15. Plats: Medicon Village, Scheelevägen 2, Lund.

Cantargia: Q3 enligt plan (Redeye) 2017-11-08 11:01. I morse presenterade Cantargia sin rapport för årets tredje kvartal. Inga överraskningar Investor Relations: christian@borsveckan.se 070-571 65 88 Övrig annonsering: ola@adprofit.se 070-968 50 91 Stockholm, September 25, 2018 — Nasdaq (Nasdaq: NDAQ) announces that Cantargia AB (short name: CANTA), a small cap company within the health care sector, today will start trading of its shares Cantargia is not a large company by global standards.
Erik thoren chimney cleaning

Newsroom. Cantargia AB Scheelevägen 27 SE-223 63 Lund, Sweden E-mail: info@cantargia.com Switch board: +46(0)46 2756260 Investor relations.

Frill is fiercly on the side of its consumers and will deliver affordable healthy nutrition.
Ordinarie arbetstid

Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.

Our development program includes the product candidate CAN04, which is in phase IIa of the clinical studies, as well as our development project CAN10.

Cantargia is not a large company by global standards. It has a market capitalization of kr1.5b, which means it wouldn’t have the attention of many institutional investors. In the chart below, we can see that institutional investors have bought into the company. Let’s delve deeper into each type of owner, to discover more about Cantargia.

2019-04-26 · STOCKHOLM, April 26, 2019 /PRNewswire/ -- The shareholders of Cantargia AB (publ) are invited to the Annual General Meeting on Monday, 27 May 2019, at 4 p.m.

Bevaka ämnet för att hålla dig uppdaterad om Cantargia. 2021-03-30 · The Investor Relations website contains information about Colgate-Palmolive Company's business for stockholders, potential investors, and financial analysts.